Bios Partners
Bios Partners is a venture capital firm focused on identifying and investing in advanced biotech opportunities in overlooked and under-invested markets across the U.S. The firm aims to disrupt geographic favoritism in venture capital by supporting compelling scientific ventures in the Central U.S. that are often undervalued. Bios Partners is driven by a mission to cultivate these companies and bring innovative biotech solutions to market.
Bios Partners
Portfolio
Focused on the development and commercialization of novel therapeutics for high impact cancers and inflammatory diseases.
#Pharmaceutical
Focused on synaptic health and restoration in neurodegenerative disorders through a pipeline of disease modifying small molecule drug candidates.
#Biopharmaceutical
Developing novel small molecule therapies for the topical treatment of presbyopia.
#Pharmaceutical
Developing a next-generation, non-invasive, transpalpebral microcurrent electrical stimulation device to treat patients with visual acuity loss due to retinal degeneration.
#Medical Devices
Mission is to treat diseases using its breakthrough technology platform called Immune System Programming (ISP™), which modifies a patient’s B cells to produce gene-encoded medicines for rare genetic diseases.
#Biotechnology
Focused on delivering a novel off-the-shelf cell therapy for the treatment of cancer.
#Biopharmaceutical
Innovating the repurposing, revitalization and development of precision therapeutics in oncology using machine learning, genomics, and AI.
#Biopharmaceutical
Formed to leverage decades of leading research in orphan, pulmonary indications for which there are unmet medical needs.
#Biopharmaceutical
Advancing a breakthrough technology designed to prevent the death of key retinal cells caused by the activation of the Fas pathway.
#Biopharmaceutical
Developing ocular AAV gene therapies to address a large pipeline of rare genetic blinding conditions that have no current treatment options.
#Biotechnology
Developing an innovative, enhanced macrophage cell therapy platform for the treatment of a broad range of solid tumors.
#Biotechnology
Focused on leveraging its engineered perlecan domain V to develop first-in-class treatments for serious neurogenerative disorders such as stroke.
#Biotechnology
Focused on the treatment of monogenic CNS disease with an extensive AAV gene therapy pipeline.
#Biotechnology
Focused on leveraging its engineered fibroblast growth factor-1 protein (eFGF-1) technology platform to develop first-in-class pharmacologic treatments for serious corneal endothelial diseases and epithelial disorders.
#Biotechnology